BioNTech and DualityBio Moving ADC into Phase III for HER2 Low Breast Cancer
Antibody-drug conjugates (ADC) are one of the fastest-growing anticancer drugs. BioNTech’s licensed ADC is now in Phase III. According to a report in BioSpace, BioNTech is attempting to compete with…